Stokes Family Office LLC Has $2.17 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Stokes Family Office LLC decreased its position in Pfizer Inc. (NYSE:PFE) by 18.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 75,258 shares of the biopharmaceutical company’s stock after selling 17,429 shares during the period. Stokes Family Office LLC’s holdings in Pfizer were worth $2,167,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Coulter & Justus Financial Services LLC acquired a new position in Pfizer in the 4th quarter worth $396,000. Loudon Investment Management LLC boosted its stake in Pfizer by 4.0% in the 4th quarter. Loudon Investment Management LLC now owns 26,580 shares of the biopharmaceutical company’s stock worth $765,000 after purchasing an additional 1,028 shares during the period. Benjamin F. Edwards & Company Inc. boosted its stake in Pfizer by 16.4% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 170,389 shares of the biopharmaceutical company’s stock worth $4,905,000 after purchasing an additional 24,028 shares during the period. Summit Global Investments boosted its stake in Pfizer by 3.7% in the 4th quarter. Summit Global Investments now owns 93,776 shares of the biopharmaceutical company’s stock worth $2,700,000 after purchasing an additional 3,348 shares during the period. Finally, Los Angeles Capital Management LLC boosted its stake in Pfizer by 3.1% in the 4th quarter. Los Angeles Capital Management LLC now owns 29,864 shares of the biopharmaceutical company’s stock worth $860,000 after purchasing an additional 899 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Pfizer stock opened at $27.81 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The company’s 50-day moving average price is $26.88 and its two-hundred day moving average price is $28.21.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. The firm had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same quarter in the prior year, the business posted $1.23 EPS. The business’s revenue was down 19.5% compared to the same quarter last year. On average, equities research analysts predict that Pfizer Inc. will post 2.39 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.04%. Pfizer’s payout ratio is presently -2,799.53%.

Wall Street Analyst Weigh In

PFE has been the topic of several analyst reports. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Morgan Stanley boosted their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a report on Thursday. Eleven research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $36.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.